Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-18 DOI:10.1080/14796694.2025.2516408

Simin Wang, Jiyong Wu, Wenfei Zhang, Jing Nie

{"title":"Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis.","authors":"Simin Wang, Jiyong Wu, Wenfei Zhang, Jing Nie","doi":"10.1080/14796694.2025.2516408","DOIUrl":null,"url":null,"abstract":"Introduction: Temozolomide combined with radiotherapy has been widely recognized as the first-line treatment for glioblastoma. However, a standard treatment regimen for recurrent glioblastoma after treatment with temozolomide plus radiotherapy is lacking at present. This network meta-analysis aimed to assess and rank the therapeutic efficacy and safety of temozolomide plus radiotherapy combined with 11 other anti-cancer treatments in glioblastoma so as to provide valuable evidence for appropriate clinical decision-making.Methods: Eligible studies investigating the efficacy and safety of temozolomide plus radiotherapy (standard treatment) compared to combination therapies were obtained by searching PubMed, Cochrane Library, and EMBASE. Outcomes included progression-free survival, overall survival, and grade 3-5 adverse events.Results: A total of 16 studies were included in this meta-analysis. Except for autologous lymphoid effector cells specific against tumor, galunisertib, and interferon-β, other anti-cancer treatments used in combination with standard treatment resulted in a survival advantage over standard treatment alone. The combination of nimustine with standard treatment performed best in improving overall survival and progression-free survival and exhibited a favorable safety profile, making it the optimal treatment option for recurrent glioblastoma.Conclusion: After a comprehensive safety analysis, nimustine and lomustine were identified as effective drugs that could be combined with standard treatment.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251004329.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2516408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Temozolomide combined with radiotherapy has been widely recognized as the first-line treatment for glioblastoma. However, a standard treatment regimen for recurrent glioblastoma after treatment with temozolomide plus radiotherapy is lacking at present. This network meta-analysis aimed to assess and rank the therapeutic efficacy and safety of temozolomide plus radiotherapy combined with 11 other anti-cancer treatments in glioblastoma so as to provide valuable evidence for appropriate clinical decision-making.

Methods: Eligible studies investigating the efficacy and safety of temozolomide plus radiotherapy (standard treatment) compared to combination therapies were obtained by searching PubMed, Cochrane Library, and EMBASE. Outcomes included progression-free survival, overall survival, and grade 3-5 adverse events.

Results: A total of 16 studies were included in this meta-analysis. Except for autologous lymphoid effector cells specific against tumor, galunisertib, and interferon-β, other anti-cancer treatments used in combination with standard treatment resulted in a survival advantage over standard treatment alone. The combination of nimustine with standard treatment performed best in improving overall survival and progression-free survival and exhibited a favorable safety profile, making it the optimal treatment option for recurrent glioblastoma.

Conclusion: After a comprehensive safety analysis, nimustine and lomustine were identified as effective drugs that could be combined with standard treatment.

Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251004329.

查看原文本刊更多论文

TMZ + RT联合其他药物治疗胶质母细胞瘤的疗效和安全性：一项网络meta分析。

替莫唑胺联合放疗已被广泛认为是胶质母细胞瘤的一线治疗方法。然而，对于替莫唑胺加放疗后复发的胶质母细胞瘤，目前缺乏标准的治疗方案。本网络荟萃分析旨在对替莫唑胺联合放疗联合其他11种抗癌治疗胶质母细胞瘤的疗效和安全性进行评价和排序，为临床合理决策提供有价值的依据。方法：通过检索PubMed、Cochrane Library和EMBASE，获得替莫唑胺加放疗（标准治疗）与联合治疗的疗效和安全性比较的符合条件的研究。结果包括无进展生存期、总生存期和3-5级不良事件。结果：本meta分析共纳入16项研究。除了针对肿瘤特异性的自体淋巴效应细胞、galunisertib和干扰素-β外，其他抗癌治疗与标准治疗联合使用比单独标准治疗具有生存优势。尼莫司汀联合标准治疗在改善总生存期和无进展生存期方面表现最佳，并表现出良好的安全性，使其成为复发性胶质母细胞瘤的最佳治疗选择。结论：经综合安全性分析，尼莫司汀、洛莫司汀为有效药物，可与标准治疗联合使用。协议注册：www.crd.york.ac.uk/prospero标识为CRD420251004329。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.